Jun 23, 2017 by David LiangAbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to KnowCould the world's best-selling drug have a protégé?
Jun 14, 2017 by David LiangAmicus Therapeutics: Is This Biotech an Orphan Underdog?After months of crazy volatility, the stock seems to have made up its mind on which direction to go: up
Jun 13, 2017 by David LiangCelgene's Next Blockbuster: What You Need to KnowCould Celgene's newest drug finally get this company the respect it deserves?
Jun 7, 2017 by David LiangOmeros: Can the Growth Story Continue?After a 60% increase since the start of 2017, can shares continue to move higher?
Jun 5, 2017 by David LiangZogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?Does Zogenix stand a chance against the cannabis king?
May 29, 2017 by David LiangWith Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory?Shares of Synergy are down, but things are looking up for this GI gem
May 28, 2017 by David LiangTwo Red Hot Biotechs With Big Near-term Catalysts AheadJune will be a pivotal month for shareholders of Portola Pharmaceuticals and Neos Therapeutics
May 26, 2017 by David LiangCould This Tiny Biotech Be the David to Mylan's EpiPen Goliath?Adamis is working on an EpiPen alternative, and the payoff could be huge
Apr 25, 2017 by David LiangBiogen and Alzheimer’s: There’s a Fundamental Problem HereBiogen's "moonshot" will likely end in failure
Apr 25, 2017 by David LiangAcadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment MarketAfter a significant pullback in April, is now the right time to jump into Acadia?
Apr 18, 2017 by David LiangAxovant: A New CEO Doesn't Change AnythingA hedge fund founder and a once-failed drug are a recipe for disaster
Apr 17, 2017 by David LiangWhy Shares of Portola Pharmaceuticals Are Up Over 60% in 2017A combination one-two punch has left investors cheering
Apr 12, 2017 by David LiangAmgen's Offering a Money Back Guarantee for Repatha. Will It Be Enough?After a slow start, are sales of Repatha finally about to pick up?
Apr 7, 2017 by David LiangSanofi Buying Flexion: A Smart Move? Will Sanofi acquire anything? Or is this deal smarter than it seems?
Apr 3, 2017 by David LiangBill Ackman Just Gave Up on Valeant. Should You Too?What lessons should investors learn from Ackman's greatest mistake?
Mar 31, 2017 by David LiangAurinia Pharmaceuticals: Where to From Here? After dropping more than 30% off its highs, is now the time to buy this baby biotech?
Mar 28, 2017 by David LiangBattle in the Boardroom: What's Next for ImmunomedicsWill VenBio successfully negotiate a higher bid for IMMU-132?
Mar 28, 2017 by David LiangWhy Shares of Immunomedics Inc Are up an Astounding 89% in 2017Will shares move higher? Or will a boardroom battle leave this biotech cruising for a bruising?
Mar 24, 2017 by David LiangAfter Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?Beneath the surface, Rigel has been gearing up for an explosive 2017
Mar 24, 2017 by David LiangOmeros: Power in the PipelineThis tiny biotech could be Alexion's worst nightmare
